Healthcare • NASDAQ
According to Zyberno, VERACYTE, INC. (VCYT) shows a Value Trap signal — GREAT BUSINESS (83/100) with an apparent Margin of Safety of +28.3%, but a Brina Gap of -14.8% reveals the current price still assumes faster growth than the business can deliver.
According to Zyberno's DCF model, VERACYTE, INC. (VCYT) trades at $43.34 against an estimated intrinsic value per share of $60.44 — a +28.3% Margin of Safety based on Owner Earnings of $155.34M TTM, projected at 71.9% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -14.8% weakens the case: based on the company's ROIC (9.0%) and reinvestment rate (-14.4%), the business can fundamentally grow at -1.3% — but the current enterprise value implies the market expects 13.5%. This places VCYT in the Value Trap quadrant of the Brina Matrix — a value-trap signal where the apparent discount is undermined by overpriced growth expectations. Zyberno's model translates this into a 5-year expected return of 28.3% annually.
Over the trailing twelve months, VCYT generated $155.34M in Owner Earnings. Capital was deployed as follows: $10.82M invested in capital expenditures. Reinvestment rate: -14.4%. Owner Earnings have grown at 71.9% annually over the trailing five years using log-linear regression.